- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02654327
pRotective vEntilation With Veno-venouS Lung assisT in Respiratory Failure (REST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute hypoxaemic respiratory failure requiring mechanical ventilation is a major cause of morbidity and mortality. A significant proportion of affected patients will have the Acute Respiratory Distress Syndrome (ARDS). Mechanical ventilation is often required to provide adequate gas exchange and although it is life-saving in this setting, it is also now known to contribute to the morbidity and mortality in the condition. Ventilators delivering high pressures and volumes cause regional over distension in the injured lung resulting in further inflammation and non-cardiogenic pulmonary oedema. The release of inflammatory mediators from the damaged lung causes systemic inflammation leading to multi-organ failure and death.
The few interventions that have been shown to reduce the high mortality in these patients have targeted ventilator-induced lung injury (VILI). A landmark trial by the ARDSNet trials group found that ventilating patients with acute hypoxaemic respiratory failure secondary to ARDS with a lung protective strategy aiming for a reduced tidal volume of 6ml/kg predicted body weight (PBW) and a maximum end-inspiratory plateau pressure (Pplat) ≤ 30cmH2O decreased mortality from 40% (in the conventional arm treated with tidal volume less than 12ml/kg PBW) to 31%.
Extracorporeal carbon dioxide removal (ECCO2R) in association with mechanical ventilation offers a potentially attractive solution to permit tidal volume reduction to less than 6ml/kg PBW and to achieve low plateau pressures (< 25cmH2O). Using these extracorporeal circuits, carbon dioxide can be 'dialysed' out of the blood while the lungs are ventilated in a more protective manner. In recent years, more efficient veno-venous devices have become available. These have replaced arterio-venous devices and have the advantage of not requiring arterial puncture. These can achieve carbon dioxide removal with relatively low extracorporeal blood flows (0.4-1 l/min) requiring only a smaller dual lumen venous catheter. In addition these ECCO2R devices use more biocompatible materials making the device more resistant to clot formation and cause less platelet and clotting factor consumption. Therefore only minimal systemic anticoagulation is required which reduces the likelihood of bleeding complications. These devices are now comparable to renal dialysis equipment, which is routinely used safely as standard care in ICUs in the United Kingdom.
Together this highlights the need for a large randomised controlled trial to establish whether VV-ECCO2R in acute hypoxaemic respiratory failure can allow the use of a more protective ventilatory strategy and is associated with improved patient outcomes. Importantly, if there was no benefit, the trial would provide evidence to stop the widespread adoption of an expensive and ineffective or potentially harmful treatment in this setting.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Belfast, United Kingdom
- Belfast Health and Social Care Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Invasive mechanical ventilation using positive end expiratory pressure (PEEP) ≥ 5cmH2O
- Acute and potentially reversible cause of acute respiratory failure as determined by the treating physician
- Within 48 hours of the onset of hypoxemia as defined by Pa02/Fi02 less than or equal to 20kPA
Exclusion Criteria:
- Age < 16 years old
- Intubated and mechanically ventilated via an endotracheal or tracheostomy tube ≥ 7 days (168 hours) up to the time of randomisation
- Ability to maintain Vt to ≤ 3ml/kg PBW while maintaining pH ≥ 7.2 as determined by the treating physician
- Receiving, or decision to commence, ECMO in the next 24 hours
- Mechanical ventilation using high frequency oscillation ventilation or airway pressure release ventilation
- Untreated pulmonary embolism, pleural effusion or pneumothorax as the primary cause of acute respiratory failure
- Acute respiratory failure fully explained by left ventricular failure or fluid overload (May be determined by clinical assessment or echocardiography/cardiac output monitoring)
- Left ventricular failure requiring mechanical support
- Contra-indication to limited systemic anticoagulation with heparin
- Unable to obtain vascular access to a central vein (internal jugular or femoral vein)
- Consent declined
- Treatment withdrawal imminent within 24 hours
- Patients not expected to survive 90 days on basis of premorbid health status
- DNAR (Do Not Attempt Resuscitation) order (excluding advance directives) in place
- Severe chronic respiratory disease requiring domiciliary ventilation (except for sleep disordered breathing)
- Severe chronic liver disease (Child Pugh >11)
- Platelet count < 40,000 mm3 (Prior to catheter insertion)
- Previously enrolled in the REST trial
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard Care
Standard care with conventional lung protective mechanical ventilation
|
|
Experimental: ECCO2R to enable lower tidal volume mechanical ventilation
VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
|
In the intervention arm a dual lumen catheter will be inserted into a central vein.
VV-ECCO2R is commenced and managed as per study manual.
Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation.
Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All cause mortality
Time Frame: 90 days after randomisation
|
90 days after randomisation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tidal volume (ml/kg Predicted Body Weight)
Time Frame: day 2 and day 3 after randomisation
|
day 2 and day 3 after randomisation
|
Ventilator free days
Time Frame: 28 days after randomisation
|
28 days after randomisation
|
Duration of ventilation in survivors
Time Frame: 28 days after randomisation
|
28 days after randomisation
|
Need for Extracorporeal Membrane Oxygenation (ECMO)
Time Frame: 7 days after randomisation
|
7 days after randomisation
|
Mortality rate
Time Frame: 28 days, 6 months and 1 year after randomisation
|
28 days, 6 months and 1 year after randomisation
|
Health Related Quality of Life
Time Frame: 6 months and 1 year after randomisation
|
6 months and 1 year after randomisation
|
Adverse Event Rate
Time Frame: 28 days
|
28 days
|
Health & Social Care Service costs
Time Frame: 6 months and 1 year after randomisation
|
6 months and 1 year after randomisation
|
St George Respiratory Questionnaire
Time Frame: 1 year after randomisation
|
1 year after randomisation
|
Need for home oxygen
Time Frame: 6 months and 1 year after randomisation
|
6 months and 1 year after randomisation
|
Post Traumatic Stress Syndrome Questionnaire (PTSS-14)
Time Frame: 1 year after randomisation
|
1 year after randomisation
|
Montreal Cognitive Assessment (MoCA-BLIND) or AD8 Dementia Screening Interview (AD8)
Time Frame: 1 year after randomisation
|
1 year after randomisation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Right Ventricular function
Time Frame: Baseline & Day 2/Day 3
|
Change in tricuspid annular plane systolic excursion (TAPSE) in cm at day 2 or 3 from randomisation measured with echocardiography
|
Baseline & Day 2/Day 3
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8. doi: 10.1056/NEJM200005043421801.
- Fitzgerald M, Millar J, Blackwood B, Davies A, Brett SJ, McAuley DF, McNamee JJ. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care. 2014 May 15;18(3):222. doi: 10.1186/cc13875.
- Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano C, Quintel M, Gattinoni L, Ranieri VM. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology. 2009 Oct;111(4):826-35. doi: 10.1097/ALN.0b013e3181b764d2.
- Bein T, Weber-Carstens S, Goldmann A, Muller T, Staudinger T, Brederlau J, Muellenbach R, Dembinski R, Graf BM, Wewalka M, Philipp A, Wernecke KD, Lubnow M, Slutsky AS. Lower tidal volume strategy ( approximately 3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med. 2013 May;39(5):847-56. doi: 10.1007/s00134-012-2787-6. Epub 2013 Jan 10.
- Boyle AJ, McDowell C, Agus A, Logan D, Stewart JD, Jackson C, Mills J, McNamee JJ, McAuley DF. Acute hypoxaemic respiratory failure after treatment with lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal: long-term outcomes from the REST randomised trial. Thorax. 2022 Oct 5:thoraxjnl-2022-218874. doi: 10.1136/thorax-2022-218874. Online ahead of print.
- McNamee JJ, Gillies MA, Barrett NA, Perkins GD, Tunnicliffe W, Young D, Bentley A, Harrison DA, Brodie D, Boyle AJ, Millar JE, Szakmany T, Bannard-Smith J, Tully RP, Agus A, McDowell C, Jackson C, McAuley DF; REST Investigators. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. JAMA. 2021 Sep 21;326(11):1013-1023. doi: 10.1001/jama.2021.13374. Erratum In: JAMA. 2022 Jan 4;327(1):86.
- Stokes JW, Gannon WD, Rice TW. Extracorporeal Carbon Dioxide Removal or Extracorporeal Membrane Oxygenation: Why Should We Care? Crit Care Med. 2021 May 1;49(5):e546-e547. doi: 10.1097/CCM.0000000000004844.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15084DMcA-AS
- 13/143/02 (Other Grant/Funding Number: NIHR HTA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Failure With Hypoxia
-
Columbia UniversityRecruitingAcute Respiratory Failure With HypoxiaUnited States
-
Hospital Sao JoaoCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Unknown
-
Hospital Clinic of BarcelonaUbikare companyUnknown
-
University Hospital, RouenCompletedAcute Respiratory Failure With Hypoxia
-
Hôpital Louis MourierUnknownHypoxemia | Acute Respiratory Failure With HypoxiaFrance
-
Jesus VillarRecruiting
-
University of ArizonaEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedMalnutrition | Acute Respiratory Failure With HypoxiaUnited States
-
Jens BräunlichRecruitingDiaphragm Issues | Respiratory Failure With Hypoxia | Respiratory Failure With Hypercapnia | Non-invasive Mechanical VentilationGermany
-
Centre Hospitalier Régional d'OrléansCompletedAcute Respiratory Failure With Hypoxia | Oxygen Inhalation Therapy | Prehospital SettingFrance
Clinical Trials on VV-ECCO2R to enable lower tidal volume mechanical ventilation
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Craig HospitalCompletedRespiratory Insufficiency | Spinal Cord InjuryUnited States
-
Fondazione Poliambulanza Istituto OspedalieroCompletedRespiratory Distress SyndromeItaly
-
Federal University of UberlandiaUnknownTraumatic Brain Injury | Mechanical Ventilation Complication | Weaning FailureBrazil
-
United States Army Institute of Surgical ResearchTerminated